Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Consolidating Translational Research Programs Is Top FY '12 Priority For NIH

Executive Summary

For National Institute of Health Director Francis Collins, the "major area of extraordinary opportunity" in his agency's fiscal 2012 budget proposal is a purportedly cost-neutral plan to pull together existing NIH-wide translational research programs under a new National Center for Advancing Translational Sciences.

You may also be interested in...



NIH Translational Center To Study Cell-Based Toxicity Tests, Offer Industry Grants

Toxicity testing is one area in which NIH Director Francis Collins expects the proposed National Center for Advancing Translational Science to help industry speed up drug development.

NIH Translational Center To Study Cell-Based Toxicity Tests, Offer Industry Grants

Toxicity testing is one area in which NIH Director Francis Collins expects the proposed National Center for Advancing Translational Science to help industry speed up drug development.

NIH Drafting NCATS Budget Plan For Congress

Planned National Center For Advancing Translational Sciences could take a "process engineering" approach to drug development, NIH Director Francis Collins says.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS053136

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel